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Abstract
Background: Serum is an ideal source of biomarker discovery and proteomic profiling studies are continuously
pursued on serum samples. However, serum is featured by high level of protein glycosylations that often cause
ionization suppression and confound accurate quantification analysis by mass spectrometry. Here we investigated
the effect of N-glycan and sialic acid removal from serum proteins on the performance of label-free quantification
results.
Results: Serum tryptic digests with or without deglycosylation treatment were analyzed by LC-MALDI MS and
quantitatively compared on the Expressionist Refiner MS module. As a result, 345 out of 2,984 peaks (11.6%)
showed the specific detection or the significantly improved intensities in deglycosylated serum samples (P < 0.01).
We then applied this deglycosylation-based sample preparation to the identification of lung cancer biomarkers. In
comparison between 10 healthy controls and 20 lung cancer patients, 40 peptides were identified to be
differentially presented (P < 0.01). Their quantitative accuracies were further verified by multiple reaction
monitoring. The result showed that deglycosylation was needed for the identification of some unique candidates,
including previously unreported O-linked glycopeptide of complement component C9.
Conclusions: We demonstrated here that sample deglycosylation improves the quantitative performance of
shotgun proteomics, which can be effectively applied to any samples with high glycoprotein contents.
Background
Since analyses of the serum proteome hold great pro-
mise for non-invasive detection of cancers and other
diseases, various techniques for quantitative proteomic
profiling have been developed to identify novel protein
biomarkers [1,2]. These include labeling methods using
stable isotopes such as ICAT (Isotope-coded affinity
tags) [3],
13CNBS (2-nitrobenzenesulfenyl) [4], SILAC
(Stable isotope labeling with amino acids in cell culture)
[5] and iTRAQ (Isobaric tags for relative and absolute
quantification) [6]. Control and test samples are labeled
with reagents with different isotopic composition of
12/13C,
14/15Na n d / o r
16/18O, and detected simulta-
neously by mass spectrometry so that the intensities of
isotopically resolved peak-pairs (or peak groups) repre-
sent the quantitative ratio of control and test samples.
Although the precision of quantification is very high
(typically 10% relative standard deviation) [7] because of
the identical separation and detection, isotopic labeling
limits the number of samples to be directly compared,
which makes it unsuitable for analysis of a large number
of clinical samples needed for biomarker discoveries. In
contrast, label-free quantification methods deal with
independently-acquired mass spectrometry data from
essentially unlimited number of samples. Quantification
based on ion intensities (extracted ion chromatograms)
is known to have at least three orders of linear dynamic
range [8,9], and can potentially cover wide proteome in
complex samples such as serum. It is advantageous that
label-free systems do not involve sample mixing prior to
detection because target proteins that are only presented
in test samples are effectively diluted by mixing with
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Therefore, label-free quantification has emerged as an
alternative approach for biomarker discovery, which
requires sufficient sample sizes to overcome individual
variability in clinical samples and technical bias in sam-
ple preparation and analysis batch [10].
High content of glycoproteins is another feature of
serum that should be considered when performing
quantitative proteomic analysis. Recent advances in gly-
coproteomic analysis using mass spectrometry have
made it possible to exhaustively identify N-linked glyco-
peptides and their glycosylation sites [11,12]. These
techniques involve enrichment of glycopeptides followed
by enzymatic cleavage of N-glycans in order for efficient
mass spectrometric analysis. Deglycosylation can be
coupled with the incorporation of
18O stable isotope
resulting in +3 Da mass shift of asparagine residues,
which allows deterministic identification of glycosylation
sites [13]. As these studies indicated, most of serum
proteins are heavily glycosylated, however, potential
effect of glycopeptides on ionization suppression of co-
existing peptides had been overlooked. Glycopeptides
carry large, hydrophilic carbohydrate moieties, which
can cause substantial ionization suppression [14], ham-
pering precise quantification particularly at low-concen-
tration range.
To elucidate the extent to which the ionization of
peptides is interfered by glycopeptides, the first part of
this study describes the changes caused by serum degly-
cosylation in the MS peak profiles obtained by label-free
shotgun proteomic analysis. Having shown the utility of
deglycosylation, we next applied this principle to the
biomarker screening of lung cancer. Because of the vast
number of incidence and high mortality rate, lung can-
cer is considered to be one of the highest priorities for
biomarker development. Using the serum samples of 10
healthy control, 10 early-stage (Stage I-II) cases and 10
advanced stage (Stages IIIb-IV) cases, we conducted a
study that uniquely combined sample deglycosylation,
label-free MALDI and multiple reaction monitoring
(MRM) mass spectrometry [15] and verified the result
by western blotting. Taken together, we show herein
that enzymatic removal of carbohydrate moieties results
in recognizable improvement in the data quality of shot-
gun proteomics in terms of sensitivity and reproducibil-
ity, which should facilitate quantitative analysis of
glycoprotein-rich samples.
Results
Quantitative MS analysis of deglycosylated serum
In order to examine the effect of deglycosylation on data
content and quality, tryptic digest of serum proteins was
prepared with or without the removal of N-glycans and
sialic acids (n = 6), and analyzed on the LC-MALDI
label-free quantification platform as summarized in Fig-
ure 1. Figure 2 shows the 2-dimensional MS signal
intensity maps after data processing by Expressionist
Refiner MS (Genedata). In total, 27,357 single peaks
were detected, comprising 4,444 groups of peaks each
representing unique peptide species (termed “peak clus-
ters”). Examples of the differences in the peak profile
between deglycosylated and untreated samples are illu-
strated in the 2D map. The broken box in Figure 2a
shows emergence of prominent peaks, and the expanded
views in Figure 2c and 2d (arrows) illustrate the loss of
intact glycopeptide peaks. The peak clusters subjected to
comparative analysis were selected by eliminating peaks
that were not presented in all of the 6 replicate runs.
This filtering was performed separately for deglycosy-
lated and untreated samples, yielding 2,984 and 2,610
peak clusters, respectively. Deglycosylation thus resulted
in 14.3% increase in the number of reproducibly detect-
able peaks. The signal intensities of these peak profiles
were then directly compared by t-test as summarized in
the volcano plot (Figure 3). 221 peak clusters displayed
altered intensities, of which 188 were higher in deglyco-
sylated samples and 33 peak clusters vice versa (P <
0.01). Present/absent search revealed that 157 peak clus-
ters were found specifically in deglycosylated samples
(Figure S-1, Additional File 1). Combined, 345 of 2,984
peak clusters (11.6%) detected in deglycosylated samples
were enhanced by deglycosylation, as opposed to 33 of
2,610 peak clusters (1.3%) in untreated serum.
The composition of the peak profiles was analyzed by
exhaustive MS/MS analysis, resulting in 1,735 peptide
identifications, including 153 originally-glycosylated pep-
tides that were identified with
18O-incorporated N-gly-
cosylation sites (Table S-2, Additional File 1). By
matching the peptide IDs to the statistical analysis, we
found that 97 of 345 peak clusters overrepresented in
deglycosylated serum were originally-glycosylated pep-
tides. These peak clusters emerged as the product of
deglycosylation and accounted for most of the major
fold-changes in the volcano plot as indicated with
squares in Figure 3. The remaining 248 peak clusters, as
well as the 33 peak clusters that diminished by deglyco-
sylation, were non-glycopeptides. There were no appar-
ent features common to these peptides. Rather, signal
intensities were affected by the local peptide composi-
tion, such that alleviation of suppressive analytes led to
signal enhancement and emergence of competing ana-
lytes led to diminished signal. The result shown here,
that the number of enhanced peaks was by far greater
than those that diminished, suggest that the ionization
suppression effect exerted by intact glycopeptides was
more extensive than the deglycosylated counterpart.
To investigate whether deglycosylation had any effect
on the quality of quantitative data, reproducibility of six
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Figure 1 Schematic of the LC-MALDI label-free quantification with deglycosylation.
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Figure 2 Representative 2-dimesional signal intensity maps visualizing the peptide profiles of (A) tryptic digest of deglycosylated
serum, and (B) untreated serum, within the range of m/z 800-4000, and 25-110 minutes of retention time. An example of obvious peak
appearance in deglycosylated serum is indicated by broken boxes. (C) and (D) display the expanded views of the closed box in deglycosylated
sample and untreated sample, respectively. The rectangles outlining the MS signal represent peak detection and their color coordination
represents peak clustering.
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Page 3 of 12replicating runs was evaluated by calculating the correla-
tion coefficients of the intensities of 2,356 clusters that
were detected in all 12 runs. The correlation coefficients
were calculated for all 15 possible combinations of 6
individual replicates within the experimental group.
They ranged from 0.895 to 0.916 with mean value 0.899
(n = 15) in the untreated group and from 0.898 to 0.944
with mean value 0.914 (n = 15) in the deglycosylated
group, suggesting that deglycosylation generally results
in more reproducible data than the untreated (P <
0.002, t-test). Furthermore, coefficients of variation (CV)
of the signal intensities for the same 2,356 peak clusters
were calculated and compared between the two experi-
mental groups (Figure 4). The frequency distribution of
CV showed that deglycosylationtreatement resulted in
slightly lowering the median CV from 34% to 31%. It is
clear from these data that the effect of deglycosylation
well extends to non-glycosylated peptides and enhances
sensitivity and reproducibility.
Lung cancer biomarker screening
Deglycosylation-LC-MALDI platform was applied to the
profiling of serum proteins for lung cancer biomarker
screening. Control and lung cancer sera were immuno-
depleted, deglycosylated, purified on SDS-PAGE, in-gel
digested and analyzed by LC-MALDI in the same way
as described above. 30 mass chromatograms were pro-
cessed simultaneously on Expressionist Refiner MS, and
23,453 peaks were detected, which were grouped into
6,186 peak clusters. Then we compared the two experi-
mental groups, control (n = 10) and lung cancer (n =
20) by t-test and identified 63 peak clusters showing P <
0.01. In addition, 13 peak clusters were selected that
have valid value of less than or equal to 2 in one experi-
mental group and greater than 50% valid value propor-
tion in the other. The total of 76 clusters was manually
inspected and retrospective MS/MS was acquired by
selecting the highest-expressing sample and the fraction
spot of maximum elution for optimum MS/MS acquisi-
tion efficiency. As a result, 25 candidate proteins, com-
prising 40 candidate peptides, were identified (Table 1).
Next, these candidates were verified at peptide level by
the MRM-based relative quantification analysis using the
same preparation batch of serum tryptic digest as used
for MALDI MS analysis as it is previously reported that
LC-MALDI measurement is the most significant source
of technical variability above sample preparation [16]
(see Table S-3, Additional File 1 for the list of MRM
transitions). This strategy was aimed at eliminating
false-positive results from the long list of candidates and
facilitating the selection of appropriate target for valida-
tion study. Of the 23 peptides that we found working
MRM transitions, 11 peptides showed significant corre-
lation (P < 0.05 by Pearson’s correlation coefficient) in
results obtained by MRM and MALDI MS, and 10 pep-
tides (6 proteins) fulfilled P <0 . 0 5i nb o t ha n a l y s e s .
These peptide candidates were derived from ceruloplas-
min, complement C3, complement component C9,
inter-alpha-trypsin inhibitor heavy chain H3, inter-
alpha-trypsin inhibitor heavy chain H4 and kininogen-1.
The quantification results were summarized as dot-plots
in Figure 5 to illustrate the potential performance of the
10 peptides as biomarker candidates. Raw data was nor-
malized to the total detection and the samples were
grouped as normal control, early stage (Stage I/II) and
advanced stage (stage IIIb/IV) lung cancer cases. As the
P-values indicate, most of the candidates showed signifi-
cant response to cancer state even at early stages.
Further verification was performed by western blotting
of complement C3 protein. Interestingly, expression of
Figure 3 Volcano plot showing the difference in the peptide
profiles of deglycosylated and untreated serum sample. Crosses
represent peak clusters identified as normal peptides or not
identified in the analysis, and squares represent deglycosylated
peptides identified with +3 Da modification.
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Figure 4 A frequency distribution plot of the coefficients of
variations (CV) calculated for each of the 2,356 common peak
clusters. Bars represent the frequency percentage and lines
represent the cumulative frequency. Filled bars and boxes, replicates
with deglycosylation; blank bars and crosses, untreated replicates (n
= 6).
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Page 4 of 12Table 1 List of lung cancer biomarker candidates screened by label-free MALDI MS and their verification result on
MRM.
MALDI MS MRM
Uniprot
ID
Protein Name Peptide Sequence t-test
† Log2
(LC/Control)
t-test
‡ Log2
(LC/Control)
Correlation
Coefficient
P04217 Alpha-1B-glycoprotein CEGPIPDVTFELLREGETKAVK - 0.67 - - -
FALVREDR 3.8E-03 -0.38 0.13 0.24 0.315
P01011 Alpha-1-antichymotrypsin EQLSLLDRFTEDAK 1.4E-03 0.80 0.077 0.33 0.106
FTEDAKRLYGSEAFATDFQDSAAAK 4.6E-03 0.58 - - -
PQDTHQSR 5.6E-03 0.84 - - -
P43652 Afamin DGLKYHYLIR 1.1E-03 -0.93 - - -
P02746 Complement C1q
subcomponent subunit B
GNLCVNLMR 6.5E-03 0.87 - - -
P00736 Complement C1r
subcomponent
CLPVCGKPVNPVEQR - 0.42 - - -
DYFIATCK 6.9E-03 0.49 0.15 0.14 -0.238
P00450 Ceruloplasmin YTVNQCR 0.017 1.1 3.1E-04 0.29 0.411*
P10909 Clusterin YVNKEIQNAVNGVK 0.01 0.33 0.19 -0.87 -0.015
P06681 Complement C2 TAVDHIREILNINQK 2.7E-03 1.4 0.051 0.23 N/A
P01024 Complement C3 AGDFLEANYMNLQR 5.9E-05 -1.4 3.8E-04 -1.3 0.690**
ILLQGTPVAQMTEDAVDAER 2.1E-04 -1.3 0.019 -0.87 0.448*
KGYTQQLAFR 2.8E-03 -1.1 3.9E-05 -1.3 0.800**
QPSSAFAAFVKR 6.7E-03 -1.3 2.0E-03 0.24 -0.455
WLNEQR 2.5E-03 -1.0 7.8E-06 -1.5 0.521**
P01031 Complement C5 FWKDNLQHKDSSVPNTGTAR 0.012 0.67 - - -
TLRVVPEGVKR 0.066 0.80 - - -
P13671 Complement component C6 IEEADCKNKFR 0.011 1.2 - - -
P10643 Complement component C7 VFSGDGKDFYR 9.5E-03 0.81 - - -
P02748 Complement Component C9 FTPTETNKAEQCCEETASSISLHGK 2.4E-04 1.4 6.1E-03 0.49 0.472*
QYTgTSYDPELTESSGSASHIDCR 1.9E-03 1.1 3.8E-03 0.57 0.769**
P22792 Carboxypeptidase N
subunit 2
SQCTYSNPEGTVVLACDQAQCR 1.4E-03 0.56 0.062 0.16 0.372
P00748 Coagulation factor XII CTHKGRPGPQPWCATTPNFDQDQR 4.3E-03 1.2 - - -
Q9UGM5 Fetuin-B MSPPQLALNPSALLSR 3.0E-03 0.62 0.03 0.58 0.189
P02751 Fibronectin AQITGYR 1.1E-03 -0.47 0.077 -0.18 0.774**
GFNCESKPEAEETCFDKYTGNTYR 1.9E-03 -0.69 0.42 -0.11 0.146
IGFKLGVRPSQGGEAPR 5.7E-03 -0.90 - - -
P26927 Hepatocyte growth factor-like
protein
RVDRLDQR 6.1E-03 -0.57 0.013 0.38 -0.128
P18065 Insulin-like growth factor-
binding protein 2
LAACGPPPVAPPAAVAAVAGGAR 2.5E-03 0.67 - - -
Q06033 Inter-alpha-trypsin inhibitor
heavy chain H3
EHLVQATPENLQEAR 4.6E-03 0.97 3.6E-03 0.65 0.578**
Q14624 Inter-alpha-trypsin inhibitor
heavy chain H4
EKNGIDIYSLTVDSR 4.7E-04 0.65 0.062 0.40 0.368
ETLFSVMPGLK - 0.09 0.01 0.42 0.331
MNFRPGVLSSR 9.8E-03 0.40 1.0E-03 0.63 0.413*
SPEQQETVLDGNLIIRYDVDR 0.013 1.2 - - -
P03952 Plasma kallikrein CQFFTYSLLPEDCKEEKCK - -0.32 - - -
P01042 Kininogen-1 RPPGFSPF 2.0E-04 -2.0 5.1E-04 -1.74 0.876**
P27918 Properdin TCNHPVPQHGGPFCAGDATR 7.2E-04 -0.52 - - -
Q13103 Secreted phosphoprotein 24 DSGEDPATCAFQR 3.7E-03 -0.53 - - -
†: “-” indicates candidate screened by present/absent search,
‡: “-” indicates no MRM data obtained, *: P < 0.05, **: P < 0.01,
g: indicates site of O-linked glycosylation.
N/A: valid value too small for calculation of correlation threshold.
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Figure 5 Dot plots showing the relative quantifications in 10 controls, 10 early stage and 10 advanced stage lung cancer cases of the
10 candidate peptides, subtitled with SwissProt IDs and amino acid numbers in parenthesis. Diamond dots aligned to the left represent
quantification by MALDI MS, and circular dots aligned to the right by MRM, normalized and plotted on the same scale. The P-values presented
were calculated using the results of MRM.
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Page 6 of 1239 kDa subunit of C3 protein was strongly suppressed
in early-stage patients (Figure 6A). Since this subunit
was also detected by the monoclonal antibody raised
against C3d fragment (Figure S-2 Additional File 1), the
39 kDa subunit was assigned to be C3dg fragment [17].
This fragment encompasses all of the four C3 peptide
candidates identified by LC-MALDI screening, and
semi-quantitative analysis of the immunoblot (Figure
6B) almost exactly reproduced the screening result.
Moreover, C3dg fragment was shown to escape immu-
nodepletion by MARS-Hu14 column (Figure S-2).
Therefore, the apparent difference in complement C3
abundance observed in the screening was reflecting the
degree of proteolytic degradation associated with lung
cancer.
Finally, the benefit of deglycosylation in this biomarker
screening was assessed by mining the candidate peptides
from the control experiment (comparing deglycosylated
and untreated serum) and verifying whether or not
deglycosylation facilitated biomarker identification. Fig-
ure 7 shows the levels of complement component C9
peptides in the control experiment, which were clearly
overrepresented by deglycosylation. Notably, the signal
intensity of non-glycopeptide (243-267) was doubled,
reiterating the observation that non-glycopeptide was
also subject of signal enhancement by deglycosylation.
Moreover, the signal intensity of peptide (22-44) was
increased by 10-fold. Since this peptide was identified as
O-linked glycopeptide (attachment of N-acetylgalactosa-
mine and galactose as predicted from the m/z shift), the
addition of sialidase probably contributed to reduction
of glycan complexity and increased ionization efficiency.
The sialylated counterpart was not detected in the
untreated control.
Discussion
The aim of this study was to introduce deglycosylation
as a facile and universal sample preparation step in
shotgun proteomic analysis because we expected that
the undermining effect exerted by the large proportion
of glycopeptides was more extensive than previously
considered. Therefore, for the first time, we have per-
formed a direct comparison between deglycosylated and
untreated serum samples, and showed that deglycosyla-
tion actually results in improvement of the shotgun
peak profile. This was observed in terms of both acquisi-
tion of unique peaks and enhancement of existing peaks.
The acquisition of unique peaks by deglycosylation
was expected, as it is widely recognized that deglycosy-
lated peptides have much higher ionization efficiency
than the corresponding glycopeptides [18,19]. It is well
established that deglycosylation results in the detection
of “new” peaks and increases the depth of information
acquired by shotgun analysis [20,21]. However, this
study revisited the same phenomenon from different
perspective. Our novel finding was that signal enhance-
ment by deglycosylation extended up to 8% of existing
non-glycopeptide peaks (Figure 3). This result strongly
suggested that there was notable ionization suppression
effect exerted by glycopeptides on co-existing analytes,
Normal
Lung cancer stage II I
M
M
40 kDa -
A
C3dg
Lung cancer stage- I, II
Lung cancer stage- IIIb, IV
M
M
40 kDa -
40 kDa -
C3dg
C3dg
0.5
0.6
v
e
e
v
e
l B
P < 0.005
P < 0.0006
0.2
0.3
0.4
C
3
d
g
 
r
e
l
a
t
i
v
e
x
p
r
e
s
s
i
o
n
 
l
e
P 0.0006
0.1
Normal Early Advanced
Figure 6 Immunoblot verification of complement C3dg serum
levels in the study subjects. (A) Detection of 39 kDa C3dg
fragment from 0.02 μL of crude serum using anti-C3 antibody.
Lanes represent 10 subjects each of normal control, early stage lung
cancer (stage-I/II) and advanced stage lung cancer (stage-IIIb/IV). (B)
Dot plot of the data shown in (A), quantified as the ratio of C3dg
detection level to the normalization lane M, a 40 kDa size marker
that has cross-reactivity with the secondary antibody.
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Figure 7 Bar chart representing the signal intensities of
complement component C9 peptides detected from the tryptic
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Page 7 of 12and that signal intensities were enhanced through alle-
viation of suppression in deglycosylated sample. Incor-
poration of
18O into the site of deglycosylation by
H2
18O was utilized to facilitate the identification of gly-
copeptides. The potential pitfalls of this approach as
pointed out by Angel et al. [22] was circumvented by
performing deglycosylation before tryptic digestion, and
our data showed that 73% of identified glycopeptides
fulfilled the biological consensus NxT/S. This strategy
helped to confirm that only a small proportion of peaks
that were enhanced by deglycosylation were actually gly-
cosylated. We further demonstrated the evidence that
deglycosylation improves the reproducibility of replicate
measurements to some extent (Figure 4). The level of
technical variability, median CV of 31%, was comparable
to previously reported label-free quantification methods
based on LC-ESI-MS [8] or LC-MALDI MS [16].
Unfortunately, previous studies on ionization suppres-
sion effects had mainly focused on selective detection of
glycopeptides in mixtures of peptides [23], and cannot
explain the phenomenon addressed here. Separate inves-
tigation needs to be conducted in order to elucidate the
mechanism and the extent to which glycopeptides inter-
fere with the ionization of co-existing peptides.
Serum deglycosylation coupled with label-free quanti-
fication was applied to biomarker screening for lung
cancer and led to the identification of unique biomarker
candidates including the fragmentation state of comple-
ment C3, complement component C9 peptide with
novel O-linked carbohydrate and Kininogen-1 peptide
with C-terminal Phe [24]. The benefit of deglycosylation
in the biomarker screening was demonstrated by
enhanced detectability of the complement component
C9 peptides, particularly for O-linked glycopeptide
whose intact form with sialic acid was hardly detected.
Since many O-linked glycans contain sialic acid, the
data presented here demonstrates a high potential of
sialidase usage for comprehensive analysis of O-linked
glycans.
As with other label-free quantitative proteomics, more
proteins were quantified by single peptide than those
quantified by multiple peptides [25] due to the high
technical variability associated with label-free shotgun
analysis. Therefore, we employed MRM to complement
the screening by MALDI MS with the aim of eliminat-
ing false-positive results. This approach successfully
ruled out many candidates while retaining confident
candidates, as verified by western blotting experiment of
complement C3.
Complement C3 is the major component of the classi-
cal complement pathway. Upon antigenic stimulation,
C3 convertase cleaves C3 into C3a and C3b, which sub-
sequently triggers reaction cascade leading to the forma-
tion of membrane attack complex, by either the classical
or alternative pathway [17]. C3a contains a multiply
interacting motif known as anaphylatoxin [26]. Recently,
an u m b e ro fp r o t e o m i cs t u d i e sh a v ei d e n t i f i e dC 3 aa s
biomarker candidates for colon cancer [27], chronic
hepatitis C and related hepatocellular carcinoma [28],
insulin resistance/type-2 diabetes [29] and chronic lym-
phoid malignancies [30]. While upregulation of C3a is
widely reported and interpreted as an indicator of pri-
mary inflammatory response, there is limited association
reported between C3dg and cancer. C3dg is known as
the ligand of complement receptor 2 [31] and may be
critically involved in cancer recognition. The mechanism
by which the production of C3dg is suppressed in
response to the onset of lung cancer requires further
investigation.
In the Expressionist label-free quantification platform
employed here, peptide peak clusters are defined by
retention time-m/z coordinate on the 2D-map, enabling
quantitative analysis without MS/MS information that
were essential in other platforms [32-35]. The feature
that provides the ground for this concept is perfect
alignment of mass chromatograms in the retention time
dimension because slight drift is unavoidable even in
well-optimized separation system. In this respect,
Expressionist demonstrated spectacular computational
strength. The range of retention time drift in the 30 LC-
MALDI analyses performed in this study was from -5
minutes to +5 minutes, a maximum of 10 minutes
deviation, but the software was still capable of good
alignment without any obvious retention time mismatch
(data not shown). Therefore, variation in experimental
conditions, such as changing the analytical column lot,
should easily be tolerated. This feature enables integra-
tion of several, even retrospective, analyses, which is
needed for the continuous pursuit for biomarker identi-
fication and validation.
Moreover, being a server-based module, Expressionist
has greater data processing capability than other stand-
alone software. This is another advantageous feature
because, in general, attempts to increase proteome cov-
erage involve vast increase in data amount, whether it
be a multi-dimensional fractionation strategy [36,37] or
an extremely long gradient separation [38]. Importantly,
considering the fact that low-abundance analytes are
more prone to ionization suppression [39], we speculate
that the benefits of sample deglycosylation we addressed
here would take greater effect with increasing dynamic
range of detection. Such in-depth label-free analysis is
currently not available, however, we demonstrated
herein that current technology is already capable of
large-scale label-free analysis, and we addressed its
potentiality as a biomarker discovery platform. Taken
together, we believe that sample deglycosylation will
prove to be a valuable sample preparation protocol in
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glycoprotein-rich samples.
Conclusions
The studies described herein demonstrated that serum
deglycosylation has positive effect on both data content
and reproducibility through production of deglycosy-
lated peptides and possibly through alleviation of ioniza-
tion suppression by intact glycopeptides. The results
therefore suggested the role of deglycosylation as a sim-
ple, indispensible method to improve the general perfor-
mance of label-free quantification. Its first application to
serum proteomic profiling by label-free LC-MALDI MS
demonstrated that this strategy could lead to the identi-
fication of unique candidates, which could be effectively
applied to any samples with high glycoprotein contents,
such as other clinical body fluids, membrane proteomics
or secretome analysis.
Methods
Reagents
Trizma base pH 8.3, iodoacetamide, ammonium bicar-
bonate, ammonium citrate, formic acid were purchased
from Sigma (Saint Louis, MO). PlusOne grade SDS and
dithiothreitol (DTT) were purchased from GE Health-
care (Uppsala, Sweden). CHAPS was purchased from
Chemical Dojin (Kumamoto, Japan). N-glycosidase F
was purchased from Roche (Basel, Switzerland). a2-
3,6,8,9-neuraminidase was purchased from Merck
(Darmstadt, Germany). Trypsin Gold was purchased
from Promega (Madison, WI). H2
18O was supplied from
Cambridge Isotope Laboratories Inc. (Andover, MA).
Alpha-cyano-4-hydroxycinnamic acid (CHCA) was pur-
chased from Shimadzu-GLC (Kyoto, Japan). LC/MS
grade acetonitrile and 25% trifluoroacetic acid (TFA)
were purchased from Wako Pure Chemicals (Osaka,
Japan).
Serum Samples
Archived human serum samples were obtained with
informed consent from 20 patients with lung adenocar-
cinoma and at Hiroshima University Hospital. Serum
samples as normal controls were also obtained with
informed consent from 13 healthy volunteers who
received medical checkup at Hiroshima University Hos-
pital (Table S-1, Additional File 1). Serum was collected
using standard protocol from whole blood by centrifuga-
tion at 1500 × g for 10 min and stored at -150°C. This
study was approved by individual institutional ethical
committees.
Immunodepletion
20 μL serum aliquots obtained from healthy volunteer
were subjected to Multiple Affinity Removal System
(Hu-14, 4.6 mm × 100 mm, Agilent Technologies, Santa
Clara, CA) according to the manufacturer’sp r o t o c o l
using a conventional HPLC system (Shimadzu Corp.,
Kyoto, Japan). The flow-through fraction was desalted
with a protein separation column (mRP-C18, 4.6 mm ×
50 mm, Agilent Technologies). Desalted serum proteins
were dried with a SpeedVac evaporator.
Deglycosylation
All solutions in the following deglycosylation step were
freshly prepared with H2
18O. Protein aliquots were dis-
solved in 12.5 μLo f2 %S D S ,2 0m MD T T ,2 0m M
T r i z m a - b a s ep H8 . 3a n dh e a t e dt o1 0 0 ° Cf o r5m i n u t e s .
After cooling, 25 μL of 10% CHAPS, 83.4 μL2 0m M
Trizma-base pH 8.3, 1 μLN - g l y c o s i d a s eFa n d0 . 6μL
a2-3,6,8,9-neuraminidase were added in the written
order with thorough mixing. H2
18O was added in place
of the enzymes for “untreated” samples. The reaction
mixture was incubated at 37°C overnight.
Tryptic digestion
Deglycosylated proteins were reduced by 10 mM DTT
and incubated at 56°C for 15 minutes, followed by alky-
lation by 50 mM iodoacetamide at ambient temperature
for 45 minutes in dark. 20% of the total reaction mix-
ture was purified by SDS-PAGE, applying voltage until
all of the proteins had entered the separating gel. Whole
lanes were cut out and subjected to in-gel tryptic diges-
tion. Briefly, gel slices were cut into small pieces and
were washed 3 times in 30% acetonitrile 50 mM ammo-
nium bicarbonate before digesting with 200 ng of tryp-
s i ni n1 0 0μL 50 mM ammonium bicarbonate at 37°C
overnight. Peptides were extracted by 2 rounds of 50%
acetonitrile and 100% acetonitrile washes. Recovered
peptides were dried in SpeedVac and reconstituted in 10
μL of 2% acetonitrile 0.1% TFA for LC-MALDI analysis.
LC-MALDI Analysis
Serum tryptic digest with or without deglycosylation was
separated using DiNa nano-HPLC system (KYA Tech-
nologies, Tokyo, Japan). Solvent A was 2% acetonitrile
and 0.1% TFA in water and solvent B was 70% acetoni-
trile and 0.1% TFA in water. 2 μL sample, a final
amount equivalent to 0.4 μL serum, was injected onto a
trap column (L-column ODS, 5 μm, 0.3 × 5 mm, CERI,
Saitama, Japan) and loaded by 8 μL/min flow of solvent
A. At 5 min, valve was switched and the peptides were
separated by an in-house packed analytical column (L-
column ODS, 3 μm ,i n0 . 1m m×2 0 0m mc a p i l l a r y )a t
200 nL/min flow rate using the following gradient: 5
min, 2% solvent B; 6 min, 10% solvent B; 90 min, 55%
solvent B; 95 min, 100% solvent B; and 110 min, 100%
solvent B. The column end was connected directly to
the spotting tip of DiNA MAP target plate spotting
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prepared at 1.5 mg/mL concentration in 70% acetoni-
trile, 0.1% TFA and 0.03 mg/mL ammonium citrate,
which was pumped to the spotting tip at 2.2 μL/min
flow rate and therein mixed with column elution. The
mixture was deposited onto a 1536-well μFocusing plate
(Hudson Surface Technologies Inc., Newark, NJ) every
15 seconds between 20.0 to 109.75 minutes for a total
of 360 spot fractions. Mass spectrometric analysis was
performed using 4800 Plus MALDI TOF/TOF Analyzer
(AB Sciex, Foster City, CA) operated on 4000 Series
Explorer software version 3.5. For each fraction spot,
data was accumulated from 1000 laser shots in a rando-
mized raster of 400 μm diameter over mass range m/z
800-4000. The laser repeat rate was 200 Hz and the
laser power was fixed at 3500 units throughout the
experiment. 5 calibration spots comprising 6 standard
peptides were used for external calibration.
Data analysis
Individual MALDI MS raw data was exported as t2d file,
ordered in chromatographic order and imported into
Expressionist Refiner MS system (Genedata AG, Basel,
Switzerland), where they were combined and displayed
as mass chromatograms. Default processing parameters
were applied unless otherwise specified. The chromato-
gram data was first simplified by subtracting the back-
ground noise by using the following criteria: 0.3 min RT
window, 40% quantile subtraction, 0.15 point RT
smoothing. After subtraction, all data points below
threshold intensity of “100” were clipped to zero. A set
of chromatograms were then aligned in the RT direction
by nonlinear transformation, mapping the original time
onto a common universal retention time, to ensure that
equal RT values correspond to the elution of the same
compounds. The following parameters were applied: RT
transformation window, 5 min; RT search interval, 30
min; m/z window, 0.2 Da; gap penalty, 1. Peak signals
were detected by summed peak detection algorithm,
which computes a temporary averaged chromatogram
over all input chromatograms, thereby allowing them to
share the matching set of peaks with identical bound-
aries. Here, the summation windows of 0.2 Da in the m/
z direction and 1 minute in the RT direction were
selected. The detected peaks were grouped into isotopic
clusters of individual compounds by summed isotope
clustering activity, using the following parameters: mini-
mum charge, 1; maximum charge, 2; maximum missing
peaks, 1; first allowed gap position, 3; RT window, 1
min; peptide isotope shaping tolerance, 0.8.
Statistical analysis
The cluster information generated by Refiner MS was
imported into Genedata Expressionist Analyst software
for statistical analysis. The clusters were first filtered by
a valid value proportion of 100% (i.e. signal was detected
in all of the experimental replicates). All of these clus-
ters were subjected to t-test for extracting differentially
expressed clusters between the experimental groups,
where P < 0.01 was considered to be significant. Pre-
sent/absent search was performed to select for clusters
with 0 or 1 counterpart detection, which were omitted
by t-test.
Protein identification
As an exhaustive study, full MS/MS analysis was per-
formed on three of the replicate runs. Precursor peaks
were selected according to the software interpretation
algorithm, while limiting the maximum number of acqui-
sition to 10 per spot. Precursor peaks were measured in
descending order of intensity. Precursor ions were iso-
lated at 150 FWHM resolution, fragmentation was
induced without the use of collision gas at 6 kV and frag-
ment ions were further accelerated at 15 kV. Laser power
of 4200 units was used, and the acquisition was summed
over 2000 laser shots or until 4 fragment peaks exceeded
S/N 100. Protein Pilot software version 2.0 was used to
generate MS/MS peak lists for searching by MASCOT
[32] version 2.2.03 (Matrix Science, London, U.K.)
against 20345 human sequences of SwissProt version
57.14. Prior to search, a custom +3 Da modification on
asparagine residue resulting from deglycosylation in
H2
18O was defined. The search parameters were as fol-
lows: enzyme, trypsin (allow up to 2 missed cleavages);
fixed modification, carbamidomethyl; variable modifica-
tions,
18O-deglycosylation (Asn); peptide tolerance, 300
ppm; MSMS tolerance, 0.5 Da. Ion expectation score of
0.05 was used for the cut-off line for identification. For
candidate biomarker peptides that were not identified by
this method, searching was iteratively repeated in differ-
ent search parameters, such as “semitrypsin” enzyme
restriction, “N-terminal pyroglutamic acid” and “+365 Da
modification on Thr” (corresponding to O-linked N-acet-
ylhexosamine and hexose attached to a threonine resi-
due) as variable modifications.
Multiple reaction monitoring
2 μL of the serum tryptic digest analyzed by LC-MALDI
was diluted by adding 6 μL of solvent A and 4 μL of tBSA
proteomic standard (KYA Technologies) dissolved at 50
fmol/μL. 1 μL of this mixture was injected for a single ana-
lysis. Paradigm nano-HPLC system with PAL autoinjector
was used for separation. Solvent A was 2% ACN in 0.1%
formic acid, solvent B was 90% ACN in 0.1% formic acid,
and sample was loaded with 2% ACN in 0.1% TFA. The
trap column was L-column ODS, 5 μm, 0.3 × 5 mm, and
the analytical column was L-column ODS loaded in-house
directly into a sprayer tip (GL Science, Tokyo, Japan).
Toyama et al. Proteome Science 2011, 9:18
http://www.proteomesci.com/content/9/1/18
Page 10 of 12MRM was performed using 4000QTRAP mass spectro-
meter (AB Sciex) during a 13 minutes gradient (2-55% sol-
vent B) at 200 nL/min flow rate. 70 ions were monitored
simultaneously for 30 minutes, each transition with 20 ms
dwell time with 5 ms interval, taking a total of 1.75 s per
scan. Transitions were selected from series of pilot experi-
ment in which in-silico developed transitions for each pep-
tide were tested for signal intensity and specificity.
Transitions were considered as the derivative of target
peptide only when all of them responded simultaneously
and the retention time of detection matched that of LC-
MALDI data. Instrument settings were as follows: declus-
tering potential, 70; entrance potential, 10; curtain gas, 10;
collision gas, 4; ion spray voltage, 2100; ion source gas, 10;
interphase heater temperature, 150°C. Peak areas were
integrated using MultiQuant software version 1.1.0.26.
Raw data was normalized to the total signal acquired,
which includes two spiked-in BSA fragments detected at
highest intensity.
Immunoblot analysis
For the verification study, crude serum samples from fresh
aliquots for all screening sample set (except for 3 normal
controls N-3, 4, and 10, which were substituted by N-11,
12, and 13, respectively) were analyzed. 0.5 μLo fc r u d e
serum was diluted 100-fold with SDS-PAGE sample buf-
fer, boiled and 20 μL was used for immunoblot analysis.
SDS-PAGE was performed using NuPAGE Bis-Tris 4-12%
acrylamide gel with 2-morpholinoethanesulfonic acid buf-
fer system, and electroblotted onto a PVDF membrane.
The blots were probed with anti-C3 polyclonal antibody
(Sigma, product code GW20073F) diluted 5000-fold in 5%
skim milk, followed by incubation with horseradish perox-
idise-conjugated secondary antibody (Sigma, product code
A9046) diluted 10000-fold in 2% BSA. The reactivity was
visualized on X-ray films using ECL detection kit (GE
Healthcare). Immunoblot was also performed with anti-
C3d monoclonal antibody (Abbiotec, San Diego, CA) and
horseradish peroxidise-conjugated secondary antibody
(GE Healthcare) to confirm specificity of the polyclonal
antibody (Figure S-2).
Additional material
Additional file 1: Supplementary Information. This PDF file contains
the following material: Figure S-1, a histogram and summary of the
number of reproducible peaks. Figure S-2, an immunoblot showing the
specificity of antibodies used. Table S-1, the list of serum samples. Table
S-2, the list of glycopeptides identified in this study. Table S-3, the detail
of MRM transitions used for verification analysis.
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